SynAct

SYNACT.ST

Tags: SE Healthcare Biotechnology

SynAct Pharma AB Price (SYNACT.ST)

Stock Price

Low: Year Low

High: Year High

Market Cap

Fetching Data...

Enterprise Value

Fetching Data...

Shares Outstanding

32,523,854

(17.9041)%

Market Cap of SynAct (SYNACT.ST)

Market cap:

As of , SYNACT.ST has a market cap of . This makes SYNACT.ST the 181th most valuable company in the SE by market cap. Market capitalization, or market cap, is the total value of a company's outstanding shares of stock, calculated by multiplying the current stock price by the total number of shares.

Year

Beginning Of Year

End Of Year

YOY Change

Community Sentiment 0 votes

↑ 0% ↓ 0%

Description

SynAct Pharma AB, through its subsidiary, SynAct Pharma ApS, develops medicines for acute deterioration in inflammatory diseases. The company is developing AP1189, a drug candidate for the treatment of rheumatoid arthritis and idiopathic membranous glomerulonephritis. It has a partnership with the University Of Örebro to study the reduction of inflammation in vascular disease. The company was founded in 2012 and is headquartered in Lund, Sweden. Read More

Sector: Healthcare

Previous Close Fetching Data...
Range $6.55-19.69
Market Cap 772.87M
Enterprise Value No Data
Avg Volume Fetching Data...
P/E Ratio Fetching Data...
Dividend Yield Fetching Data...

Industry: Biotechnology

ceo: Mr. Jeppe Ovli Ovlesen EE, MBA
IPO Date: July, 11, 2016
Country: SE
Currency: SEK
Headquaters: No Data
Employees: 6

- Revenue from each product or segment:

No data Found

Product or Segment	Value:	% - Total	Last 3Y:

No data Found

- Revenue by Region

Product or Segment	Value:	% - Total	Last 3Y: